Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Telix Pharmaceuticals Limited (TLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: TLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -9.06% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.23B USD | Price to earnings Ratio 173.44 | 1Y Target Price 20.19 |
Price to earnings Ratio 173.44 | 1Y Target Price 20.19 | ||
Volume (30-day avg) 47043 | Beta 2.38 | 52 Weeks Range 14.01 - 30.36 | Updated Date 03/8/2025 |
52 Weeks Range 14.01 - 30.36 | Updated Date 03/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.62% | Operating Margin (TTM) 9.49% |
Management Effectiveness
Return on Assets (TTM) 7.97% | Return on Equity (TTM) 20.49% |
Valuation
Trailing PE 173.44 | Forward PE 77.52 | Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 |
Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 12.96 | Enterprise Value to EBITDA 113.13 | Shares Outstanding 334724000 | Shares Floating 282348658 |
Shares Outstanding 334724000 | Shares Floating 282348658 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Telix Pharmaceuticals Limited
Company Overview
History and Background
Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products based on targeted radiopharmaceuticals. Founded in 2015, Telix has grown through strategic acquisitions and internal development to address unmet needs in oncology and rare diseases.
Core Business Areas
- Therapeutics: Development and commercialization of radiotherapeutic products, using radiation to target and destroy cancer cells. Targeting products for prostate, kidney, and other cancers.
- Diagnostics: Development and commercialization of radiodiagnostic products, using imaging agents to detect and visualize cancer. Prostate cancer imaging is a key focus.
- Research and Development: Investing in research and development to expand its pipeline of radiopharmaceutical products.
Leadership and Structure
Telix Pharmaceuticals Limited is led by a management team with experience in radiopharmaceuticals, oncology, and drug development. The organizational structure is functional, with departments dedicated to R&D, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Illuccix (Kit for the preparation of gallium (68Ga) gozetotide injection): A PSMA-targeting PET imaging agent for prostate cancer. Illuccix is used to detect recurrent or metastatic prostate cancer. Competitors include Lantheus (LNTH) with PYLARIFY and Blue Earth Diagnostics with Axumin. Telix's revenue related to Illuccix is growing rapidly but still subject to variability.
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing due to advancements in targeted therapies and diagnostic imaging. Aging populations and increasing cancer prevalence are driving demand. The market is competitive with established players and emerging companies.
Positioning
Telix Pharmaceuticals Limited is positioned as a leader in the radiopharmaceutical market, focusing on innovative diagnostic and therapeutic products for oncology. Its competitive advantage lies in its proprietary technology and a strong pipeline of radiopharmaceutical products.
Total Addressable Market (TAM)
The global radiopharmaceutical market is expected to reach $10 billion by 2030. Telix is positioning itself to capture a significant share of this market through its expanding product portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong pipeline of radiopharmaceutical products
- Proprietary technology platform
- Experienced management team
- Global presence and distribution network
- FDA approved products
Weaknesses
- Reliance on regulatory approvals for new products
- Competition from established pharmaceutical companies
- High R&D expenses
- Manufacturing complexities with radiopharmaceuticals
Opportunities
- Expanding the product pipeline through acquisitions and partnerships
- Entering new markets and geographic regions
- Developing new applications for existing radiopharmaceutical products
- Leveraging artificial intelligence for drug discovery
Threats
- Regulatory changes and delays
- Competition from biosimilars
- Economic downturn and reduced healthcare spending
- Patent infringement and intellectual property disputes
Competitors and Market Share
Key Competitors
- LNTH
- BUEI
Competitive Landscape
Telix Pharmaceuticals Limited competes with established pharmaceutical companies and emerging players in the radiopharmaceutical market. Its advantages include its proprietary technology, strong pipeline, and experienced management team. However, it faces competition from larger companies with greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Telix Pharmaceuticals Limited has experienced significant revenue growth in recent years, driven by the commercialization of Illuccix and other products. The company is investing heavily in R&D to expand its pipeline.
Future Projections: Analyst estimates project continued revenue growth for Telix Pharmaceuticals Limited, driven by increasing adoption of its radiopharmaceutical products and expansion into new markets. Forecasts vary among analysts. You would need to get analysts forecasts from websites like Yahoo Finance or MarketWatch.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships, and the development of new radiopharmaceutical products for various oncology indications.
Summary
Telix Pharmaceuticals Limited is a growing biopharmaceutical company focused on radiopharmaceuticals, particularly in oncology. They've shown revenue growth via FDA approved products and continued expansion of their therapeutic technology. While they have a strong pipeline and experienced management, their dependence on approvals, competition from larger companies, and high R&D expenses need to be navigated carefully. Telix is well-positioned in a growing market.
Similar Companies
- LNTH
- AVEO
- NBIX
- LLY
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports (if available)
- Press releases
- SEC filings (if available)
- Radiopharmaceutical Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change. Consult with a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telix Pharmaceuticals Limited
Exchange NASDAQ | Headquaters North Melbourne, VIC, Australia | ||
IPO Launch date 2024-11-14 | Co-Founder, MD, Group CEO & Executive Director Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telixpharma.com |
Full time employees - | Website https://telixpharma.com | ||
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.